Pioglitazone: post-stenting benefits in patients without diabetes

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1485, 2005-01, pp. : 15-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pioglitazone Improves Diabetic Dyslipidaemia in Patients with Type 2 Diabetes Mellitus with or without Lipid-Lowering Therapy

By Schöfl Christof  

Clinical Drug Investigation, Vol. 25, Iss. 5, 2005-01 ,pp. : 341-345

Adis International

Access to resources Recommend Favorite

Pioglitazone is Effective Therapy for Elderly Patients with Type 2 Diabetes Mellitus

By Rajagopalan R.   Perez A.   Ye Z.   Khan M.   Murray F.T.  

Drugs & Aging, Vol. 21, Iss. 4, 2004-01 ,pp. : 259-271

Adis International

Access to resources Recommend Favorite

Pioglitazone: benefits beyond glycaemic control

By  

Inpharma, Vol. 1, Iss. 1465, 2004-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Postmarketing Surveillance Study of the Efficacy and Tolerability of Pioglitazone in Insulin-Resistant Patients with Type 2 Diabetes Mellitus in General Practice

By Schöfl C.  

Clinical Drug Investigation, Vol. 23, Iss. 11, 2003-01 ,pp. : 725-734

Adis International

Access to resources Recommend Favorite

Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus: Comparison with Other Oral Antihyperglycaemic Agents

By Derosa Giuseppe  

Drugs, Vol. 70, Iss. 15, 2010-10 ,pp. : 1945-1961

Adis International

Access to resources Recommend Favorite